Calliditas Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Calliditas Value Chain Analysis gives you a clear, structured view of how the company creates value across support and primary activities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying; purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Calliditas Therapeutics needs lean firm infrastructure because it serves a rare-disease market that depends on tight oversight, clean governance, and fast regulatory execution. In 2025, that means keeping strategy, finance, quality systems, and compliance aligned across the US and EU so development work and commercial activity stay in step. This structure matters because a small error in labeling, reporting, or reimbursement can slow launch and raise cost.
Human Resource Management
Calliditas depends on a small, highly skilled team in clinical development, regulatory affairs, pharmacovigilance, medical affairs, and rare-disease commercialization. With only 1 core commercial product in the portfolio, focused hiring improves speed, oversight, and launch control. In 2025, this lean talent mix matters because rare-disease execution needs precise compliance and fast field feedback.
Technology Development
Calliditas's technology development centers on TARPEYO, the only FDA-approved therapy for IgA nephropathy, plus renal and autoimmune pipeline work. The NefIgArd phase 3 program followed 199 patients and showed a 27% lower 24-hour urine protein-to-creatinine ratio at 9 months, supporting differentiation. Ongoing formulation and life-cycle studies help extend TARPEYO's clinical use and support future label expansion.
Procurement
In 2025, Calliditas Therapeutics' procurement was a key control point because the business depended on qualified external suppliers for drug substance, packaging, and clinical materials. Tight supplier oversight helps protect GMP quality, reduce supply disruption risk, and keep costs disciplined in a niche therapy market.
That matters when a single quality slip can delay batches, trials, and revenue.
Lean 2025 Support Kept TARPEYO on Track
In 2025, Calliditas Therapeutics' support activities stayed lean: firm infrastructure, specialist talent, and supplier control all backed TARPEYO execution. The business relied on tight US-EU compliance, a small expert team, and qualified external manufacturing partners to protect GMP quality and keep one core product moving.
| Support area | 2025 fact |
|---|---|
| Core product | 1 |
| NefIgArd patients | 199 |
| Proteinuria cut | 27% |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Calliditas' inbound logistics is built around validated vendors for API, excipients, packaging, and clinical trial materials, because rare-disease drugs need tight control and steady supply. In 2025, supply security mattered more than bulk volume, since one delayed lot can disrupt launch or trial timelines. This makes vendor qualification, cold-chain handling, and quality checks the key value drivers.
Operations
Calliditas Therapeutics' Operations were built around TARPEYO, so clinical development, FDA/regulatory work, quality oversight, and outsourced manufacturing had to stay tightly aligned. In 2025, that focus mattered because one approved product means any delay in batch release, supplier control, or CMC changes can hit launch readiness and pipeline timing fast. For a single-product model like Calliditas Therapeutics, operations are the main gate between R&D and sales.
Outbound Logistics
Calliditas' outbound logistics for TARPEYO relied on tightly controlled shipment to specialty pharmacies and approved channel partners, because IgAN patients need fast, uninterrupted access. In 2025, the business sits under Asahi Kasei after the SEK 11.8 billion acquisition, so distribution now runs through a larger pharma network. Lot traceability, release timing, and on-time fill rates are still key to U.S. and EU continuity.
Marketing and Sales
Calliditas's marketing and sales in 2025 focused on nephrologists and other rare-disease prescribers treating adults with IgAN, so reach is narrow but high value. In the United States and the European Union, growth depends on payer access, reimbursement support, and disease education, because IgAN affects about 25 per million people each year and prescribers need clear evidence to start treatment.
Service
Service in Calliditas Value Chain Analysis centers on patient support, adherence help, reimbursement navigation, and medical-information response after prescribing. This matters because rare-disease drugs face high access friction, so even short delays in prior authorization or specialty-pharmacy setup can slow starts and reduce realized demand. For Calliditas, strong post-sale service helps keep patients on therapy, supports safety follow-up, and protects long-duration treatment value in chronic kidney disease care.
TARPEYO Execution Drives Calliditas Therapeutics in 2025
Calliditas Therapeutics' primary activities in 2025 were built around TARPEYO, with R&D, regulatory work, outsourced manufacturing, and quality control keeping one-product execution tight. The SEK 11.8 billion Asahi Kasei acquisition widened distribution, but lot release and supply control stayed critical. Sales targeted IgAN, a rare disease affecting about 25 per million people a year. Service focused on adherence and reimbursement support.
| Activity | 2025 driver |
|---|---|
| Operations | TARPEYO, batch control |
| Outbound logistics | Specialty pharmacy flow |
| Marketing and sales | IgAN access, payer support |
| Service | Adherence, reimbursement help |
Get Your Copy
Calliditas Reference Sources
This is the actual Calliditas Value Chain Analysis document you'll receive upon purchase – no sample, no placeholder, just the full professional version. The preview below is taken directly from the final report, so you know exactly what you're getting. Once purchased, the complete document unlocks immediately.
Frequently Asked Questions
Calliditas Therapeutics' value chain is anchored by TARPEYO and a narrow rare-disease footprint. The model is built around 1 lead commercial product, 2 approved markets, and 5 primary activities that convert regulatory approval into sales. That concentration makes execution more focused, but it also makes growth highly dependent on one branded asset.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.